Skip to main content
SpringerLink
Log in

Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals

  • Correspondence
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kappelhoff BS, Huitema AD, Yalvac Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 2005; 44(8): 849–61

    Article  PubMed  CAS  Google Scholar 

  2. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306(1): 287–300

    Article  PubMed  CAS  Google Scholar 

  3. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005; 40(9): 1358–61

    Article  PubMed  CAS  Google Scholar 

  4. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15(1): 1–5

    Article  PubMed  CAS  Google Scholar 

  5. Hasse B, Gunthard HF, Bleiber G, et al. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 2005; 40(3): E22–3

    Article  PubMed  CAS  Google Scholar 

  6. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 2004; 18(18): 2391–400

    PubMed  CAS  Google Scholar 

  7. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 2005; 10(4): 489–98

    PubMed  CAS  Google Scholar 

  8. Desta Z, Ward BA, Flockhart DA, et al. Genetic variants of CYP2B6 decrease rate of efavirenz metabolism in vitro [abstract no. PI-61]. Clin Pharmacol Ther 2005; 77(2): P24

    Article  Google Scholar 

  9. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by nonnucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19(7): 1038–45

    Article  PubMed  Google Scholar 

  10. Alonso-Villaverde C, Coll B, Gomez F, et al. The efavirenzinduced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. Aids 2005; 19(3): 341–2

    PubMed  CAS  Google Scholar 

  11. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359(9300): 30–6

    Article  PubMed  CAS  Google Scholar 

  12. Winzer R, Langmann P, Zilly M, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8(12): 531–4

    PubMed  CAS  Google Scholar 

  13. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72(1): 1–9

    Article  PubMed  CAS  Google Scholar 

  14. Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44(11): 1273–81

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK

    David J. Back, Andrew Owen & Saye H. Khoo

Authors
  1. David J. Back
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saye H. Khoo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Back, D.J., Owen, A. & Khoo, S.H. Population Pharmacokinetics of Efavirenz in an Unselected Cohort of HIV-1-Infected Individuals. Clin Pharmacokinet 45, 213–214 (2006). https://doi.org/10.2165/00003088-200645020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200645020-00006

Keywords

Search

Navigation